Results 111 to 120 of about 52,371 (280)

Data_Sheet_1_A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation.docx

open access: yes, 2020
Diffuse large B cell lymphoma (DLBCL) is associated with aggressive clinical cases and poor prognosis despite recent advances in disease treatment. In activated B-cell-like (ABC)-DLBCL, the most severe damaged signaling pathways converge to aberrantly ...
Tete Li (7464080)   +11 more
core   +1 more source

A Reassessment of the Validity of the Routine Lymph2Cx Assay for the Cell‐of‐Origin Assignment of Diffuse Large B‐Cell Lymphoma

open access: yesEuropean Journal of Haematology, EarlyView.
Reassessment of the Lymph2Cx assay revealed reduced ABC representation and enrichment of the Lymph2Cx‐defined GCB category by cases classified as ABC or UNC by gold‐standard profiling, with potential implications for prognostic stratification and clinical trial interpretation.
Maria Carmela Vegliante   +12 more
wiley   +1 more source

Gastric Outlet Obstruction as The First Presenting Sign of Gastric Lymphoma: A Case Report

open access: yesJurnal Penyakit Dalam Indonesia
Gastric lymphoma often presents with non-specific symptoms, contributing to delayed diagnosis. Gastric Outlet Obstruction (GOO) is a potential complication that may occur in patients with gastric lymphoma.
Lie Khie Chen   +3 more
doaj   +1 more source

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives Baseline systemic inflammation has emerged as a determinant of outcome after CD19‐directed CAR‐T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma (LBCL) receiving commercial CAR‐T cells, focusing ...
Eugenio Galli   +10 more
wiley   +1 more source

Br J Haematol [PDF]

open access: yes
Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts.

core  

Features of DLBCL-NOS patients used for super-SILAC.

open access: yes, 2019
Features of DLBCL-NOS patients used for super-SILAC.
L. E. van der Meeren (7490675)   +6 more
core   +1 more source

Charting the course of Sjögren's disease: A historical analysis of scientific progress

open access: yesEuropean Journal of Oral Sciences, EarlyView.
Abstract Sjögren's disease (SjD) bears the name of the Swedish ophthalmologist Henrik Sjögren. His 1933 doctoral thesis on keratoconjunctivitis sicca ignited interest, yet much remains under debate. SjD is an autoimmune disorder that primarily affects the exocrine glands, particularly the salivary and lacrimal glands, leading to a dryness of the eyes ...
Diego Ustárroz Cantali   +3 more
wiley   +1 more source

High-Power Haematoxylin and Eosin Staining Showing DLBCL

open access: yes, 2013
High-Power Haematoxylin and Eosin Staining Showing ...
Catherine Burton (10254)
core   +1 more source

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

open access: yesThe FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy